Angst, J (2007). Psychiatric diagnoses: the weak component of modern research. World Psychiatry 6, 94–95.
Bech, P (2001). Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. International Journal of Neuropsychopharmacology 4, 337–345.
Bech, P (2007). Dose-response relationship of Pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 40, 163–168.
Bech, P (2009). Fifty years with the Hamilton scales for anxiety and depression. Psychotherapy and Psychosomatics 78, 202–211.
Bech, P, Allerup, P, Gram, LF, Reisby, N, Rosenberg, R, Jacobsen, O, Nagy, A (1981). The Hamilton Depression Scale. Evaluation of objectivity using logistic models. Acta Psychiatrica Scandinavica 63, 290–299.
Bech, P, Allerup, P, Reisby, N, Gram, LF (1984). Assessment of symptom change from improvement curves on the Hamilton Depression Scale in trials with antidepressants. Psychopharmacology 84, 276–281.
Bech, P, Cialdella, P, Haugh, M, Birkett, MA, Hours, A, Boissel, JP, Tollefson, GD (2000). A meta-analysis of randomised controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression. British Journal of Psychiatry 176, 421–428.
Bech, P, Gram, LF, Dein, E, Jacobsen, O, Vitger, J, Bolwig, TG (1975). Quantitative rating of depressive states. Acta Psychiatrica Scandinavica 51, 161–170.
Bech, P, Kajdasz, DK, Porsdal, V (2006). Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology 188, 273–280.
Bech, P, Tanghøj, P, Andersen, HF, Overø, K (2002). Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology 163, 20–25.
Bech, P, Tanghøj, P, Cialdella, P, Friis Andersen, H, Pedersen, AG (2004). Escitalopram dosee–response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. International Journal of Neuropsychopharmacology 7, 283–290.
Beck, AT (1973). The Diagnosis and Management of Depression. University of Pennsylvania Press: Philadelphia.
Bent-Hansen, J, Lunde, M, Klysner, R, Andersen, M, Tanghøj, P, Solstad, K, Bech, P (2003). The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression. Pharmacopsychiatry 6, 313–316.
Bollini, P, Pampallona, S, Tbaldi, G, Kupelnick, B, Munizza, C (1999). Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 174, 297–303.
Boyer, P, Montgomery, S, Lepola, U (2008). Efficacy, safety and tolerability of fixed-dose desvenlafaxine 50 mg and 100 mg/day for major depression in a placebo-controlled trial. International Clinical Psychopharmacology 23, 248–253.
Cohen, J (1976). Statistical Power Analysis for the Behavioural Sciences. Lawrence Erlbaum, New York.
Detke, MJ, Wiltse, CG, Mallinckrodt, CH, Mc Namara, RK, Demitrack, MA, Bitter, I (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European Neuropsychopharmacology 14, 457–470.
Entsuah, R, Shaffer, M, Zhang, J (2002). A critical examination of the sensitivity of unidimensional subscales derived from the Hamilton Depression Rating Scale to antidepressant drug effects. Journal of Psychiatric Research 36, 437–448.
European Union (1994). Guidelines on psychotropic drugs: antidepressant medical products. European Neuropsychopharmacology 4, 62–65.
Geddes, JR, Carney, SM, Davies, C, Furukawa, TA, Kupfer, DJ, Frank, E, Goodwin, GM (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 61, 653–661.
Hamilton, M (1967). Development of a rating scale for primary depressive illness. British Journal of social and Clinical Psychology 6, 278–296.
Hamilton, M (1986). The Hamilton Depression Scale. In Assessment of Depression (ed. Sartorius, N. and Ban, T. A.), pp. 143–152. Springer: Berlin.
Hamilton, M (1987). Assessment of psychopathology. In Human Psychopharmacology. Measures and Methods (ed. Hindmarch, I. and Stonier, P. D.), pp. 1–18. Wiley: Chichester.
Hays, RD, Hadorn, D (1992). Responsiveness to change: an aspect of validity, not a separate dimension. Quality of Life Research 1, 73–75.
Hays, RD, Morales, LS, Reise, SP (2000). Item response theory and health outcome measurement in the 21st century. Medical Care 38 (Suppl. 2), 28–42.
Hedges, LV, Olkin, I (1985). Statistical Methods for Meta-analysis. Academic Press: Orlando.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT (2008). Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Public Library of Science Medicine 5, 260–268.
Kuhn, R (1958). The treatment of depressive states with G 22355 (imipramine hydrochloride). American Journal of Psychiatry 115, 459–464.
Kuhn, R (1970). The imipramine story. In Discoveries in biological psychiatry (ed. Ayd, F. J. and Blackwell, B.), pp. 205–217. Lippincott: Philadelphia.
Lauritzen, L, Odgaard, K, Clemmesen, L, Lunde, M, Ôhrström, J, Black, C, Bech, P (1996). Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatrica Scandinavica 94, 241–251.
Leber, P (1996). The role of the regulator in the evaluation of the acceptability of new drug products. In Psychotropic Drug Development (ed. Healy, D. and Doogan, D. P.), pp. 69–77. Chapman & Hall Medical: London.
Lingjærde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgren, K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica (Suppl.) 334, 1–100.
Mayer, DY (1975). Psychotropic drugs and the ‘anti-depressed’ personality. British Journal of Medical Psychology 48, 349–357.
Montgomery, SA, Åsberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382–389.
Øhrberg, S, Christiansen, PE, Severin, B (1992). Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatrica Scandinavica 86, 437–444.
Overall, JE (1962). The dimensions of manifest depression. Psychiatric Research 1, 239–245.
Parker, G (2009). Antidepressants on trial: how valid is the evidence. British Journal of Psychiatry 194, 1–3.
Porter, AMW (1970). Depressive illness in a general practice. A demographic study and a controlled trial of imipramine. British Medical Journal 1, 773–778.
Pinder, RM, Zivkov, M (1998). On demonstrating the correct dose for new antidepressants. In Clinical Pharmacology in Psychiatry: Finding the Right Dose of Psychotropic Drugs (ed. Balant, L. P., Benitez, J., Dahl, S. G., Gram, L. F., Pinder, R. M. and Potter, W. Z.), pp. 31–42. European Commission: Brussels.
Rasch, G (1980). Probalistic Models for Some Intelligence and Attainment Tests. University of Chicago Press: Chicago.
Rasmussen, A, Lunde, M, Poulsen, DL, Sørensen, K, Qvitzau, S, Bech, P (2003). A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 44, 216–221.
Riskind, JH, Beck, AT, Brown, G, Steer, RA (1987). Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton Scales. Journal of Nervous and Mental Disorders 175, 474–479.
Robinson, RG, Jorge, RE (2009). Prevention of first-episode depression: progress and potential. British Journal of Psychiatry 194, 296–297.
Ruhé, HG, Dekker, JJ, Peen, J, Holmen, R, de Jonghe, F (2005). Clinical use of the Hamilton Depression Rating scale: is increased efficiency possible? A post hoc comparison of Hamilton Depression Rating Scale, Maier and Bech subscales, Clinical Global Impression, and Symptom Checklist-90 scores. Comprehensive Psychiatry 46, 417–427.
Rush, AJ, Beck, AT, Kovacs, M, Hollon, S (1977). Comparative efficacy of cognitive therapy and imipramine in the treatment of depressed outpatients. Cognitive Therapy and Research 1, 17–37.
Ryle, G (1949). The Concept of Mind. Hutchinson: London.
Santen, G, Gomeni, R, Danhof, M, Pasqua, OD (2008). Sensitivity of the Hamilton Depression Scale to response and its consequence for the assessment of efficacy. Psychiatric Research 42, 100–109.
Smith, A, Tranganzo, E, Harrison, G (1969). Studies on the effectiveness of antidepressant drugs. Psychopharmacology Bulletin (Suppl.), 1–53.
Steinmeyer, EM, Möller, H-J (1992). Facet theoretic analysis of the Hamilton-D scale. Journal of Affective Disorders 25, 53–62.
Turner, EH (2008). Efficacy of antidepressants. British Medical Journal 336, 516–517.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, B (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 358, 252–60.
Young, LPH, Plosker, GL (2008). Desvenlafaxine extended release. CNS Drugs 22, 1061–1069.